Additional file 2 of The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer

Additional file 2: Supplemental Figure 2. Regulatory network and Sankey diagram of the 5 frlncRNAs. (A) The interactive network of frlncRNAs and mRNAs using Cytoscape. (B) Sankey diagram demonstrated the relationship between the 5 frlncRNAs, ferroptosis mRNAs and risk type

Additional file 1 of The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer

Additional file 1: Supplemental Figure 1. Heatmap showed the expression profiles of the 35 lncRNAs in PCa samples and normal controls

Additional file 7 of The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer

Additional file 7: Supplemental Table 2. A total of 669 frlncRNAs were identified by Pearson’s correlation analysis in 495 prostate patients with absolute correlation coefficient >0.30 and P < 0.001

Additional file 6 of The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer

Additional file 6: Supplemental Table 1. The PCR primers and siRNAs sequences in this study

Additional file 4 of The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer

Additional file 4: Supplemental Figure 4. The most significantly enriched pathways enriched in the low-risk group [20–22]. (A) propanoate metabolism. (B) valine leucine and isoleucine degradation. (C) butanoate metabolism. (D) adherens junction. (E) peroxisome. (F) citrate cycle tca cycle. (G) fatty acid metabolism. (H) n glycan biosynthesis. (I) sphingolipid metabolism. All FDR<0.25 and P<0.05

Additional file 3 of The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer

Additional file 3: Supplemental Figure 3. The predictive ability of the model in all PCa patients. (A-B) The risk score and BCR states of every individual. (C-D) Effective clustering ability of risk score based on the 5 frlncRNAs in all patients. (E) Patients with high risk scores had shorter PSA-free survival expectancy. (F) ROCs showed the capability of risk score to predict BCR in all patients

Additional file 5 of The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer

Additional file 5: Supplemental Figure 5. Downstream of BCRP3. (A-B) Verification of knockdown efficiency. (C) Effects of BCRP3 on RB1, STAT3 and LAMP2 mRNA levels

Additional file 8 of The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer

Additional file 8: Supplemental Table 3. Univariate Cox analysis was conducted and 183 lncRNAs were verified to be associated with BCR

Additional file 9 of The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer

Additional file 9: Supplemental Table 4. Baseline characteristics of enrolled cases